T3 Defense Inc. DFNS

Industrials SIC 8742 - Services-Management Consulting Services Nasdaq

known as Nukkleus Inc.) (the "Company" or "T3") was formed on May 24, 2019 under the name Brilliant Acquisition

Corporation for the purpose of engaging in a business combination. On June 23, 2023, Brilliant Acquisition Corporation, a British Virgin

Islands company (prior to the Merger "Brilliant", and following the Merger, a Delaware corporation "Nukkleus"),

entered into an Amended and Restated Agreement and Plan of Merger (as amended by the First Amendment to the Amended and Restated Agreement

Last close 10.24 2026-09-04
Market cap $17.0M 2026-06-30 share count
52-week range 3.70 - 335.00

Valuation FY2025 figures against the last close

P/S
P/E1.3x
P/FCF
EV/EBITDA
Dividend yield
Diluted EPS7.96

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue $5.9M$21.3M$21.5M
Cost of revenue $4.9M$21.6M$22.2M
Gross profit $998.5K-$343.1K-$661.4K
SG&A $28.1M$6.7M
Total operating expenses $32.6M$7.1M$14.7M$10.5M
Operating income -$32.6M-$7.1M-$14.7M-$11.1M-$670.9K-$148.0K-$20.7K
Interest expense $154.0K$387.0K$1.8K
Pre-tax income $76.6M-$7.4M-$17.4M-$11.8M
Income tax $9.0K
Net income $78.5M-$8.5M-$17.4M-$11.8M-$599.1K-$317.7K-$20.7K
EPS, basic 8.45-4.93-13.84-1.21-0.10
EPS, diluted 7.96-4.93-13.84-1.21-0.10-0.09-0.04
Shares, diluted (wtd. avg.) $9.2M$1.7M$1.3M$9.8M$6.1M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents $2.6M$6.9M$7.8K$2.4M$1.2M$712.8K$27.7K
Short-term investments $250.0K
Receivables $506.0K
Total current assets $13.6M$9.1M$2.9M$3.7M$47.7M$46.7M
Property, plant and equipment $101.0K
Goodwill $7.7M
Other intangibles $16.0K$19.3K$33.0K$8.1M
Total assets $202.4M$9.1M$3.4M$18.4M$47.7M$46.7M$210.0K
Accounts payable $124.0K$70.0K$138.7K$51.7K$309.6K$25.9K$427
Short-term debt $12.0K$17.5K$17.5K
Total current liabilities $43.5M$171.4M$9.1M$7.5M$1.9M$328.0K$205.7K
Long-term debt $1.6M
Total liabilities $45.2M$172.5M$9.5M$7.5M$2.1M$575.7K$205.7K
Retained earnings -$122.5M-$201.1M-$31.8M-$14.3M-$5.7M-$3.7M-$20.7K
Total equity -$19.8M-$163.3M-$6.2M$10.9M$9.2M$154.8K$4.3K

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating cash flow -$6.2M-$3.8M-$1.2M$1.6M-$430.9K-$137.1K-$20.2K
Depreciation and amortisation $4.0K$273.7K$264.2K
Stock-based compensation $18.8M$230.0K$370.9K$1.9M
Capital expenditure $31.0K
Investing cash flow -$179.8M$133.0K-$1.1M-$35.0K-$1.4M-$46.0M
Financing cash flow $182.0M$3.0M$418.3K-$40.4M$1.4M$46.8M$47.9K

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-097287.

Others in SIC 8742

TickerCompanyMarket capP/ERevenue growth
BAH Booz Allen Hamilton Holding Corp $8.76B 10.6x -6.4%
G Genpact LTD $6.27B 11.9x 6.6%
FCN FTI CONSULTING, INC $4.19B 18.4x 2.4%
EXPO EXPONENT INC $3.25B 33.0x 4.2%
HURN Huron Consulting Group Inc. $2.52B 26.6x 11.9%
ASTH Astrana Health, Inc. $2.14B 83.6x 56.4%
ICFI ICF International, Inc. $1.58B 17.8x -7.3%
BWMN Bowman Consulting Group Ltd. $735.5M 58.1x 14.9%